Gyre Therapeutics, Inc.

Healthcare

NASDAQ:GYRE · NASDAQ Capital Market

Market Cap $589.93M Beta 4.92 P/E (TTM) -88.3

$6.25 -0.15%

+$0.00 today

52W Low $5.44High $9.42

Vol 0.06M · Avg 0.09M

EPS (TTM) -$0.07Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

-19.56%

Period High

$8.87

Period Low

$5.56

Latest

$6.25

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Erasca, Inc.

NASDAQ:ERAS

$4.28B

ArriVent BioPharma, Inc. Common Stock

NASDAQ:AVBP

$1.48B

MoonLake Immunotherapeutics

NASDAQ:MLTX

$1.42B

Iovance Biotherapeutics, Inc.

NASDAQ:IOVA

$1.40B

MBX Biosciences, Inc. Common Stock

NASDAQ:MBX

$1.37B

MeiraGTx Holdings plc

NASDAQ:MGTX

$1.03B

Astria Therapeutics, Inc.

ATXS

$718.13M

CytomX Therapeutics, Inc.

NASDAQ:CTMX

$471.21M

Keros Therapeutics, Inc.

NASDAQ:KROS

$336.46M

Anavex Life Sciences Corp.

NASDAQ:AVXL

$244.19M

What is the latest GYRE filing?

The latest filing shown is 8-K dated Jun 16, 2026.

How many recent filings does GYRE have?

Intrinsic Alpha currently shows 20 recent filings for GYRE.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.